FDA Drug Safety Advisory Committee Will Consider Adverse Event Reporting Alternatives
This article was originally published in The Pink Sheet Daily
Committee will discuss pros and cons of the current system of safety signal detection and quantification at its May 18-19 meeting. Members will also assess recent steps by FDA to supplement the passive Adverse Event Reporting System.
You may also be interested in...
Claims data collected on prescriptions filled through the Medicare drug benefit will be used by outside groups to produce evidence on drugs' safety and effectiveness. FDA advisory committees, AHRQ and IoM could help determine study priorities, CMS says.
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said